Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Research analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Climb Bio in a report released on Wednesday, May 14th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($0.18) for the quarter, down from their prior forecast of ($0.15). The consensus estimate for Climb Bio's current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio's Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($1.18) EPS, FY2028 earnings at ($1.84) EPS and FY2029 earnings at ($2.85) EPS.
Climb Bio (NASDAQ:CLYM - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.16).
Climb Bio Price Performance
NASDAQ CLYM opened at $1.29 on Monday. The firm has a fifty day moving average of $1.26. The stock has a market cap of $87.17 million, a P/E ratio of -0.61 and a beta of -0.12. Climb Bio has a 12 month low of $1.05 and a 12 month high of $9.58.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new position in shares of Climb Bio in the 1st quarter valued at $27,000. XTX Topco Ltd acquired a new stake in Climb Bio during the 1st quarter worth $34,000. Nuveen LLC acquired a new stake in Climb Bio during the 1st quarter worth $48,000. Bank of New York Mellon Corp acquired a new stake in Climb Bio during the 1st quarter worth $79,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Climb Bio during the 1st quarter worth $86,000. 69.76% of the stock is owned by hedge funds and other institutional investors.
About Climb Bio
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
